Long QT Syndrome 3 Latest Advances

Journal: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

Published: November 16, 2017

Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.

Journal: Heart rhythm

Published: February 15, 2017

Long QT Syndrome 3 Latest Advances

Find the Latest Research About Long QT Syndrome 3

COMPUTATIONAL ANALYSIS OF THE NOVEL LQT3 MUTATIONS G1481V AND Q1491H IN MYOCARDIAL AND PURKINJE CELLS.

COMPUTATIONAL ANALYSIS OF THE NOVEL LQT3 MUTATIONS G1481V AND Q1491H IN MYOCARDIAL AND PURKINJE CELLS.

Life-threatening events in patients with LQT3 on and off beta-blockers: Insights from a case series.

Life-threatening events in patients with LQT3 on and off beta-blockers: Insights from a case series.

Signature ECG 3: A case of long QT 3 syndrome (LQT3).

Signature ECG 3: A case of long QT 3 syndrome (LQT3).

Long QT Syndrome: LQT3 Variant Presenting in a Bradycardic Newborn.

Long QT Syndrome: LQT3 Variant Presenting in a Bradycardic Newborn.

Diagnostic lacunae and implications of an automated implantable cardioverter defibrillator implantation in a child with type 3 Long QT (LQT3) syndrome.

Diagnostic lacunae and implications of an automated implantable cardioverter defibrillator implantation in a child with type 3 Long QT (LQT3) syndrome.

Mexiletine Treatment for Neonatal LQT3 Syndrome: Case Report and Literature Review.

Mexiletine Treatment for Neonatal LQT3 Syndrome: Case Report and Literature Review.

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3.

Gating Properties of Mutant Sodium Channels and Responses to Sodium Current Inhibitors Predict Mexiletine-Sensitive Mutations of Long QT Syndrome 3.

Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.

Experimental analysis of the onset mechanism of TdP reported in an LQT3 patient during pharmacological treatment with serotonin-dopamine antagonists against insomnia and nocturnal delirium.

Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.

Characterization of a novel LQT3 variant with a selective efficacy of mexiletine treatment.

Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.

Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.

Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3).

Clinical aspects of the three major genetic forms of long QT syndrome (LQT1, LQT2, LQT3).

Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.

Phenotypic variability in LQT3 human induced pluripotent stem cell-derived cardiomyocytes and their response to antiarrhythmic pharmacologic therapy: An in silico approach.